The misuse of recombinant bovine somatotropin (rbST) to increase milk yield involves buffalo not just cows. Screening methods to identify rbST-treated cattle have already been proposed. However, there have been no studies on prolonged periods with a high number of animals. In this study, we developed a new enzyme-linked immunosorbent assay (ELISA) to measure the serum responsiveness towards rbST, based on an acid-stripping procedure and relatively simple integral calculation dilution curves. We also applied the analysis to 640 serum and 96 milk samples collected from 16 buffalo treated with rbST and 16 controls, over a period of approximately three months. Its suitability as a screening method, in compliance with EU law, was also assessed. A bi-factorial approach was also evaluated, including the measurement of insulin-like growth factor 1 concentration in serum. Results showed that our ELISA could be used on its own for screening purposes, without the need to assess other biomarkers. Copyright © 2016 John Wiley & Sons, Ltd.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/dta.1994 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Obesity as an influencing factor for the occurrence of caffeine-induced effects in women.
Nutr Metab Cardiovasc Dis
December 2024
Department of Basic Medical Sciences, Faculty of Medicine and Health Sciences, Rovira i Virgili University, Escorxador, 43003, Reus, Spain. Electronic address:
Beckground And Aims: Individuals with a higher body fat percentage may have higher serum levels of caffeine and its metabolites and process caffeine more slowly than individuals with a lower body fat percentage, so the aim of this study is to compare the occurrence of positive and negative effects of caffeine in nonobese and obese women.
Methods And Results: One hundred and sixty women were included in the study. Body fat was determined using the mBCA 515 SECA analyzer.
Exploiting the synergistic effect of β-cyclodextrin functionalized-multi-walled carbon nanotubes and Zn-MOF for the detection of endocrine-disrupting chemical methylparaben.
Anal Chim Acta
February 2025
Biofuel and Renewable Energy Research Center, Department of Biotechnology, Faculty of Chemical Engineering, Babol Noshirvani University of Technology, Babol, Iran.
Background: The buildup of methylparaben (MP), a broad-spectrum antimicrobial preservative with endocrine-disrupting properties, in environmental sources, especially aquatic systems, has become a significant concern due to its adverse health effects, including allergic reactions, promoting the risk of developing cancer, and inducing reproductive disorders. Hence, introducing inexpensive and easy-to-use monitoring devices for rapid, selective, and sensitive detection and quantification of MP is highly desirable. In this context, electrochemical platforms have proven to be attractive options due to their remarkable features, such as ease of fabrication and use, short response time, and acceptable sensitivity, accuracy, and selectivity.
View Article and Find Full Text PDFINTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease.
J Prev Alzheimers Dis
January 2025
CenExel iResearch, Atlanta, GA, USA.
Background: Soluble species of multimeric amyloid-beta including globular amyloid-beta oligomers (AβOs) and linear amyloid-beta protofibrils are toxic to neurons. Sabirnetug (ACU193) is a humanized monoclonal antibody, raised against globular species of soluble AβO, that has over 650-fold greater binding affinity for AβOs over monomers and appears to have relatively little binding to amyloid plaque.
Objectives: To assess safety, pharmacokinetics, and exploratory measures including target engagement, biomarker effects, and clinical efficacy of sabirnetug in participants with early symptomatic Alzheimer's disease (AD; defined as mild cognitive impairment and mild dementia due to AD).
First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer.
J Immunother Cancer
January 2025
Medical Oncology, Sarah Cannon Research Institute, Nashville, Tennessee, USA.
Background: SL-172154 is a hexameric fusion protein adjoining the extracellular domain of SIRPα to the extracellular domain of CD40L via an inert IgG-derived Fc domain. In preclinical studies, a murine equivalent SIRPα-Fc-CD40L fusion protein provided superior antitumor immunity in comparison to CD47- and CD40-targeted antibodies. A first-in-human phase I trial of SL-172154 was conducted in patients with platinum-resistant ovarian cancer.
View Article and Find Full Text PDFProtection induced by recombinant vaccinia virus targeting the ROP4 of Toxoplasma gondii in mice.
Exp Parasitol
January 2025
Department of Medical Zoology, School of Medicine, Kyung Hee University, Seoul, 02447, Republic of Korea; Medical Research Center for Bioreaction to Reactive Oxygen Species and Biomedical Science Institute, Core Research Institute (CRI), Kyung Hee University, Seoul, 02447, Republic of Korea. Electronic address:
Toxoplasmosis is a parasitic disease affecting a significant portion of the global population, whose etiology can be attributed to the protozoan organism Toxoplasma gondii. Despite its public health importance, an efficacious vaccine to prevent human toxoplasmosis remains unavailable. To this end, we designed an experimental toxoplasmosis vaccine using recombinant vaccinia virus vectors (rVacv) expressing the T.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!